What is FidoCure?
FidoCure operates at the vanguard of veterinary medicine, providing a pioneering service that utilizes genomic testing to tailor cancer therapies for dogs. By moving beyond the limitations of traditional chemotherapy and radiation, the company offers a personalized approach that accounts for the unique genetic profile of each patient. This methodology not only improves prognoses but also provides pet parents and veterinarians with actionable insights derived from the world's largest proprietary canine cancer data set. The company's market position is defined by its commitment to scientific rigor and its ability to bridge the gap between human-grade precision medicine and veterinary clinical practice.
How much funding has FidoCure raised?
FidoCure has raised a total of $10M across 1 funding round:
Other Financing Round
$10M
Other Financing Round (2020): $10M with participation from Andreessen Horowitz, Y-Combinator, Lerer Hippeau, Borealis Ventures, Tau Ventures, and Polaris Partners
Key Investors in FidoCure
Andreessen Horowitz
A prominent venture capital firm that invests in bold entrepreneurs building the future through technology, with a strong focus on life sciences and healthcare innovation.
Y-Combinator
A premier startup accelerator and seed-stage investor known for fostering high-growth companies through mentorship and extensive network access.
Lerer Hippeau
A New York-based venture capital firm that specializes in early-stage investments, supporting founders who are redefining industry categories across enterprise and consumer sectors.
What's next for FidoCure?
Looking ahead, the strategic deployment of $10M will likely focus on scaling the company's genomic sequencing infrastructure and expanding its reach within the veterinary community. As FidoCure continues to aggregate data, the potential for predictive modeling and the development of novel therapeutic interventions becomes increasingly viable. The company is expected to prioritize partnerships with veterinary oncology centers to integrate its diagnostic platform into standard clinical workflows, thereby solidifying its role as an essential component of modern pet healthcare. This phase of growth will be critical in establishing long-term sustainability and market dominance in the burgeoning field of animal health technology.
See full FidoCure company page
